BRIEF-Antibe Announces Enrollment In Mid-Stage Trial of Pain Drug ATB-346
Reuters Staff
1 Min Read
Jan 29 (Reuters) - Antibe Therapeutics Inc:
* ANTIBE THERAPEUTICS ANNOUNCES ENROLLMENT OF FINAL SUBJECTS IN PHASE 2B GASTROINTESTINAL SAFETY STUDY OF LEAD PAIN DRUG, ATB-346 Source text for Eikon: Further company coverage: